ClinConnect ClinConnect Logo
Search / Trial NCT01151436

Global Management of Facial Rejuvenation With a New Range of Hyaluronic Acid Dermal Fillers

Launched by GALDERMA R&D · Jun 25, 2010

Trial Information

Current as of June 22, 2025

Completed

Keywords

Facial Wrinkle Correction

ClinConnect Summary

The range of fillers tested in this study includes 5 different hyaluronic acid dermal fillers: Emervel Touch, Emervel Classic, Emervel Deep, Emervel Volume and Emervel Lips.

The study will last 6 month.

Injections will be performed at baseline. If necessary, the investigator will perform touch-up injections at the following visit (3 weeks later).

Investigator and subject satisfaction will be collected through questionnaires.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Seeking tissue augmentation treatment on the face,
  • Presenting a score of 3 (Moderately deep wrinkle)or 4 (Deep wrinkle) on the Lemperle Rating Scale (LRS) of both nasolabial folds.
  • Exclusion Criteria:
  • At risk in term of precautions, warnings and contra-indication referred in the package insert of the study devices,
  • Who underwent previous injection of permanent filler in the injected area.

About Galderma R&D

Galderma R&D is a global leader in dermatological innovation, dedicated to advancing skin health through rigorous research and development. With a strong commitment to scientific excellence, Galderma focuses on creating effective and safe treatments for a variety of skin conditions, including acne, rosacea, and psoriasis. The organization collaborates with healthcare professionals and researchers worldwide to bring cutting-edge solutions to market, ensuring that patients receive the highest quality care. Through its extensive clinical trials and commitment to regulatory compliance, Galderma R&D strives to enhance the understanding of dermatological diseases and improve patient outcomes.

Locations

Arras, , France

Nice, , France

Paris, , France

Berlin, , Germany

Darmstadt, , Germany

Patients applied

0 patients applied

Trial Officials

Philippe KESTEMONT

Principal Investigator

Investigational site Nice France

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials